Pneumococcal Vaccines Market Size, Share, Opportunities, COVID 19 Impact, And Trends By Type (Conjugate Vaccines, Polysaccharide Vaccines), By Application (Routine Vaccination, Vaccination For Disease/ Infection), And By Geography - Forecasts From 2019 To 2024

Published:  May 2020 Report Code: KSI061612059 Pages: 107

The Pneumococcal vaccines market is estimated to witness a CAGR of 4.74% to reach US$10,618.805 million in 2024 from US$8,044.052 million in 2018. Pneumococcal diseases affect thousands of people every year as it is a contagious disease and can easily spread from person to person these rising incidences of pneumococcal diseases like pneumonia, meningitis, febrile bacteremia, otitis media, sinusitis, bronchitis, and others is driving the demand for pneumococcal vaccines. Pneumococcal vaccines may or may not protect against the pneumonia disease but they can reduce the effect of this disease.

The market is also being driven by the strong support of the local government and private health organizations such as UNICEF, WHO and U.S Centers for Disease Control and Prevention has recommended the pneumococcal vaccines to all the children below 2 years of age and adults above 65. According to WHO, the pneumococcal vaccine had been introduced in 134 countries by 2016 end and estimated global coverage was about 42%. Growing awareness regarding the importance of vaccination and increasing spending by the governments towards public health is fuelling the development of pneumococcal vaccines in developing countries. However, there are some side effects after getting vaccinated but there is a very low chance of getting any serious reaction.

DRIVERS
Increase in the number of pneumococcal diseases.
Favorable support by the government.

OPPORTUNITY
Pneumococcal vaccine is being introduced in cancer treatment for making antibodies to fight cancer.

INDUSTRY UPDATE
In February 2019, Pfizer accounted to investigate Serotype included in 20- Valent Pneumococcal Conjugate vaccine candidate for the prevention of Invasive disease and Pneumonia in Adults aged 18 years or above.
In May 2017, Pfizer’s pneumonia vaccine became part of the immunization program.

The major players profiled in the pneumococcal vaccines market include Pfizer, Sanofi Pasteur MSD, GSK, Merck, AstraZeneca, and Baxter International.

Pneumococcal Vaccines Market Scope:

Report Metric Details
 Market size value in 2018  US$8,044.052 million
 Market size value in 2024  US$10,618.805 million
 Growth Rate  CAGR of 4.74% from 2018 to 2024
 Base year  2018
 Forecast period  2019–2024
 Forecast Unit (Value)  USD Million
 Segments covered  Type, Application, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  Pfizer, Sanofi Pasteur MSD, GSK, Merck, AstraZeneca, Baxter International
 Customization scope  Free report customization with purchase

 

Segmentation

The Pneumococcal vaccines market has been analyzed through the following segments:

By Type
Conjugate vaccines
Polysaccharide vaccines

By Application
Routine Vaccination
Vaccination for Disease/ Infection

By Geography
North America
USA
Canada
Mexico

South America
Brazil
Argentina
Others

Europe
Germany
France
United Kingdom
Spain
Others

Middle East and Africa
Saudi Arabia
Israel
Others

Asia Pacific
China
Japan
South Korea
India
Others


Frequently Asked Questions (FAQs)

Q1. What will be the pneumococcal vaccines market size by 2024?
A1. The pneumococcal vaccines market is estimated to reach a market size of US$10,618.805 million by 2024.

Q2. What are the growth prospects for pneumococcal vaccines market?
A2. The global pneumococcal vaccines market is estimated to witness a CAGR of 4.74% during the forecast period.

Q3. What is the size of global pneumococcal vaccines market?
A3. Pneumococcal Vaccines market was valued at US$8,044.052 million for the year 2018.

Q4. Who are the major players in the pneumococcal vaccines market?
A4. The major players profiled in the pneumococcal vaccines market include Pfizer, Sanofi Pasteur MSD, GSK, Merck, AstraZeneca, and Baxter International.

Q5. What factors are anticipated to drive the pneumococcal vaccines market growth?
A5. Pneumococcal diseases affect thousands of people every year as it is a contagious disease and can easily spread from person to person these rising incidences of pneumococcal diseases like pneumonia, meningitis, febrile bacteremia, otitis media, sinusitis, bronchitis, and others is driving the demand for pneumococcal vaccines.

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. PNEUMOCOCCAL VACCINES MARKET BY TYPE
5.1. Conjugate Vaccine
5.2. Polysaccharide Vaccine
6. PNEUMOCOCCAL VACCINES MARKET BY APPLICATION
6.1. Routine Vaccination
6.2. Vaccination for Disease/ Infection
7. PNEUMOCOCCAL VACCINES MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Pfizer
9.2. Sanofi Pasteur MSD
9.3. GSK
9.4. Merck
9.5. AstraZeneca
9.6. Baxter International
LIST OF FIGURES
LIST OF TABLES

Pfizer
Sanofi Pasteur MSD
GSK
Merck
AstraZeneca
Baxter International

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us